Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma

Everolimus plus letrozole may be an effective combination for patients with recurrent endometrial carcinoma (EC), according to an oral presentation at the 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in New Orleans.¹

For this non-comparative phase 2 study, researchers randomly assigned 74 patients with advanced/recurrent EC to receive everolimus plus letrozole daily (37 patients), or tamoxifen daily plus medroxyprogesterone daily on alternating weeks (37 patients). Eligible patients received only 1 or fewer previous courses of systemic treatment.

One and 8 patients in the everolimus arm had a complete response (CR) and partial response (PR), respectively, while 2 and 6 patients in the tamoxifen arm had a CR and PR, respectively.

Seventeen patients — 10 in the everolimus arm vs 7 in the tamoxifen arm — continued therapy, and 20 patients vs 25 patients in the everolimus arm vs tamoxifen arm, respectively, had disease progression and discontinued therapy.

Grade 3 to 4 adverse events occurred at similar frequencies in both study arms; 3 patients discontinued therapy because of toxicity. The researchers noted that thromboembolic events occurred at a statistically insignificant higher rate among patients receiving tamoxifen and medroxyprogesterone.

The authors added that “further study of its activity in chemo-naive patients is warranted.”

Read more of Cancer Therapy Advisor‘s coverage of the Society of Gynecologic Oncology 2018 meeting by visiting the conference page.

Reference

1. Slomovitz BM, Filiaci VL, Coleman RL, et al. GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): a GOG Foundation study. Oral presentation at: 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 24-27, 2018; New Orleans, LA.